Top Markets
Coin of the day
BriaCell Therapeutics Corp. BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

BCTX
Rank in Stocks #18288
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages... BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Share Price
$4.32
Market Cap
$8.14M
Change (1 day)
-6.49%
Change (1 year)
-2.88%
Country
CA
Trade BriaCell Therapeutics Corp. (BCTX)

Category

Operating Margin for BriaCell Therapeutics Corp. (BCTX)
Operating Margin as of 2026 TTM: 0.00%
According to BriaCell Therapeutics Corp. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for BriaCell Therapeutics Corp. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
41.30% -
DK
35.45% -
US
24.95% -
US
25.32% -
BE
25.64% -
NL
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.